Department of Cardiothoracic Surgery, The First People's Hospital of Neijiang, Neijiang, Sichuan, China.
Sci Rep. 2024 Jan 12;14(1):1166. doi: 10.1038/s41598-024-51844-8.
The association between pretreatment albumin-to-alkaline phosphatase ratio (AAPR) and clinicopathological parameters and prognosis in lung cancer is unclear. The study aimed to identify the clinical role of pretreatment AAPR among lung cancer patients. Several databases were searched for relevant studies. The primary outcome and secondary outcome were long-term survival including the overall survival (OS) and progression-free survival (PFS) and clinicopathological characteristics, respectively. The hazard ratios (HRs) and relative risks (RRs) with 95% confidence intervals (CIs) were combined. A total of 11 publications involving 10,589 participants were included in this meta-analysis. The pooled results manifested that a lower pretreatment AAPR predicted poorer OS (HR = 0.65, 95% CI 0.59-0.71, P < 0.001) and PFS (HR = 0.68, 95% CI 0.59-0.78, P < 0.001). Furthermore, subgroup analysis for the OS and PFS based on the pathological type and treatment showed similar results and pretreatment AAPR was significantly associated with worse prognosis. Besides, pretreatment AAPR was significantly associated with male (RR = 1.08, 95% CI 1.03-1.13, P < 0.001), poor differentiation (RR = 1.33, 95% CI 1.03-1.73, P = 0.029), advanced T stage (RR = 1.25, 95% CI 1.03-1.52, P = 0.026), N stage (RR = 1.34, 95% CI 1.15-1.55, P < 0.001) and TNM stage (RR = 1.14, 95% CI 1.06-1.223, P < 0.001). Therefore, pretreatment AAPR is significantly related to prognosis and tumor stage in lung cancer and patients with a lower pretreatment AAPR are more likely to experience poor survival and advanced tumor stage.
预处理白蛋白-碱性磷酸酶比值（AAPR）与肺癌临床病理参数和预后的关系尚不清楚。本研究旨在确定肺癌患者中预处理 AAPR 的临床作用。检索了多个数据库以获取相关研究。主要结局和次要结局分别为长期生存，包括总生存（OS）和无进展生存（PFS）以及临床病理特征。使用 95%置信区间（CI）合并风险比（HR）和相对风险（RR）。共纳入 11 项研究，涉及 10589 名参与者。荟萃分析结果表明，较低的预处理 AAPR 预示着 OS（HR=0.65，95%CI 0.59-0.71，P<0.001）和 PFS（HR=0.68，95%CI 0.59-0.78，P<0.001）更差。此外，基于病理类型和治疗的 OS 和 PFS 的亚组分析也得出了相似的结果，预处理 AAPR 与预后不良显著相关。此外，预处理 AAPR 与男性（RR=1.08，95%CI 1.03-1.13，P<0.001）、低分化（RR=1.33，95%CI 1.03-1.73，P=0.029）、进展期 T 分期（RR=1.25，95%CI 1.03-1.52，P=0.026）、N 分期（RR=1.34，95%CI 1.15-1.55，P<0.001）和 TNM 分期（RR=1.14，95%CI 1.06-1.223，P<0.001）显著相关。因此，预处理 AAPR 与肺癌的预后和肿瘤分期显著相关，预处理 AAPR 较低的患者更有可能经历较差的生存和更晚期的肿瘤分期。
